AC Immune SA provided an update on positive progress in its active immunotherapy programs, with three Phase 2 trials progressing to key clinical milestones in 2024. ACI-7104.056: AC Immune's wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy, to treat Parkinson's disease (PD). Enrollment of cohort 1 in the Phase 2 VacSYn clinical trial evaluating ACI-7104.076, is completed, with 16 patients randomized, and cohort 2 enrollment and randomization has begun.

No safety concerns have been reported to date with no reports of moderate or severe adverse events. ACI-35.030: AC Immune's partnered investigational targeted active immunotherapy, selective for pathological phosphorylated Tau (pTau). As recently announced, AC Immune's development partner launched ReTain, a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical AD.

The trial will randomize approximately 500 pre-symptomatic participants with confirmed early-stage Tau pathology and treat them for a four-year period, with interim analyses potentially allowing for acceleration towards a regulatory filing.